D Thiwanka Wijeratne1, Katherine Lajkosz1, Susan B Brogly1, M Diane Lougheed1, Li Jiang1, Ahmad Housin1, David Barber1, Ana Johnson1, Katharine M Doliszny1, Stephen L Archer2. 1. From the Department of Medicine (D.T.W., M.D.L., A.H., D.B., K.M.D., S.L.A.), Institute for Clinical Evaluative Sciences Queen's (D.T.W., K.L., S.B.B., M.D.L., L.J., A.J.), Department of Surgery (S.B.B.), and Department of Public Health Sciences (M.D.L., A.J.), Queen's University, Kingston, ON, Canada. 2. From the Department of Medicine (D.T.W., M.D.L., A.H., D.B., K.M.D., S.L.A.), Institute for Clinical Evaluative Sciences Queen's (D.T.W., K.L., S.B.B., M.D.L., L.J., A.J.), Department of Surgery (S.B.B.), and Department of Public Health Sciences (M.D.L., A.J.), Queen's University, Kingston, ON, Canada. stephen.archer@queensu.ca.
Abstract
BACKGROUND: The World Health Organization recognizes 5 groups of pulmonary hypertension (PH), categorized by pathogenesis or comorbidity: 1-pulmonary arterial hypertension 2-left-heart disease, 3-lung disease and hypoxia 4-chronic thromboembolic disease, and 5-miscellaneous. The epidemiology of PH, apart from group 1, is largely unknown. METHODS AND RESULTS: We describe incidence, prevalence, comorbidities, mortality and prescribing patterns for groups 1 to 4 PH from 1993 to 2012. Case definitions are based on hospitalizations and emergency department visits, using the Institute for Clinical Evaluative Sciences data, which comprises linked databases of universal coverage health service records for Ontario residents. This cohort included 50 529 patients with PH. The annual incidence of adult PH increased from 2003 to 2012 from 24.1 to 28.7 cases/100 000 population and the annual prevalence from 1993 to 2012 from 99.8 to 127.3 cases/100 000 population, respectively. The most common form of adult PH was group 2, alone (34.2%) or combined with group 3 PH (29.3%). A diagnosis of PH increased the 1-year standardized mortality ratio 7.2-fold. Mortality in adults with PH was 13.0%, 36.4%, and 62.4%, at 30 days, 1 year, and 5 years, respectively. Mortality was highest in groups 2 and 3 and lowest in group 1. PH was present in only 3.6% of people with left heart disease, 0.7% with lung disease, and 1.4% with thromboembolic disease, suggesting that PH is a relatively rare complication of these common diseases. Children (age<16 years) accounted for 3.6% of the cohort. In children group 1 PH was most common (65.2%), and 5-year mortality was lower (21.4%) than in adults. Group 1-specific PH therapies were increasingly prescribed over time and paradoxically were often used in patients who seemed to have group 2, PH based on diagnostic codes indicating left heart disease. CONCLUSIONS: The incidence and prevalence of adult PH are increasing. Groups 2 and 3 are the most common and lethal forms of PH. This study identifies an emerging epidemic of PH that likely has substantial adverse health and economic implications.
BACKGROUND: The World Health Organization recognizes 5 groups of pulmonary hypertension (PH), categorized by pathogenesis or comorbidity: 1-pulmonary arterial hypertension 2-left-heart disease, 3-lung disease and hypoxia 4-chronic thromboembolic disease, and 5-miscellaneous. The epidemiology of PH, apart from group 1, is largely unknown. METHODS AND RESULTS: We describe incidence, prevalence, comorbidities, mortality and prescribing patterns for groups 1 to 4 PH from 1993 to 2012. Case definitions are based on hospitalizations and emergency department visits, using the Institute for Clinical Evaluative Sciences data, which comprises linked databases of universal coverage health service records for Ontario residents. This cohort included 50 529 patients with PH. The annual incidence of adult PH increased from 2003 to 2012 from 24.1 to 28.7 cases/100 000 population and the annual prevalence from 1993 to 2012 from 99.8 to 127.3 cases/100 000 population, respectively. The most common form of adult PH was group 2, alone (34.2%) or combined with group 3 PH (29.3%). A diagnosis of PH increased the 1-year standardized mortality ratio 7.2-fold. Mortality in adults with PH was 13.0%, 36.4%, and 62.4%, at 30 days, 1 year, and 5 years, respectively. Mortality was highest in groups 2 and 3 and lowest in group 1. PH was present in only 3.6% of people with left heart disease, 0.7% with lung disease, and 1.4% with thromboembolic disease, suggesting that PH is a relatively rare complication of these common diseases. Children (age<16 years) accounted for 3.6% of the cohort. In children group 1 PH was most common (65.2%), and 5-year mortality was lower (21.4%) than in adults. Group 1-specific PH therapies were increasingly prescribed over time and paradoxically were often used in patients who seemed to have group 2, PH based on diagnostic codes indicating left heart disease. CONCLUSIONS: The incidence and prevalence of adult PH are increasing. Groups 2 and 3 are the most common and lethal forms of PH. This study identifies an emerging epidemic of PH that likely has substantial adverse health and economic implications.
Authors: Garvan C Kane; Hilal Maradit-Kremers; Josh P Slusser; Chris G Scott; Robert P Frantz; Michael D McGoon Journal: Chest Date: 2010-11-11 Impact factor: 9.410
Authors: Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2009-01-22 Impact factor: 21.405
Authors: Janet E Pope; Peter Lee; Murray Baron; James Dunne; Douglas Smith; Peter S Docherty; Arthur Bookman; Maysan Abu-Hakima Journal: J Rheumatol Date: 2005-07 Impact factor: 4.666
Authors: R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg Journal: Am Heart J Date: 1997-07 Impact factor: 4.749
Authors: David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon Journal: Chest Date: 2009-10-16 Impact factor: 9.410
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Steven H Abman; Georg Hansmann; Stephen L Archer; D Dunbar Ivy; Ian Adatia; Wendy K Chung; Brian D Hanna; Erika B Rosenzweig; J Usha Raj; David Cornfield; Kurt R Stenmark; Robin Steinhorn; Bernard Thébaud; Jeffrey R Fineman; Titus Kuehne; Jeffrey A Feinstein; Mark K Friedberg; Michael Earing; Robyn J Barst; Roberta L Keller; John P Kinsella; Mary Mullen; Robin Deterding; Thomas Kulik; George Mallory; Tilman Humpl; David L Wessel Journal: Circulation Date: 2015-11-03 Impact factor: 29.690
Authors: Yi Ling; Martin K Johnson; David G Kiely; Robin Condliffe; Charlie A Elliot; J Simon R Gibbs; Luke S Howard; Joanna Pepke-Zaba; Karen K K Sheares; Paul A Corris; Andrew J Fisher; James L Lordan; Sean Gaine; J Gerry Coghlan; S John Wort; Michael A Gatzoulis; Andrew J Peacock Journal: Am J Respir Crit Care Med Date: 2012-07-12 Impact factor: 21.405
Authors: Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan Journal: J Heart Lung Transplant Date: 2018-09-14 Impact factor: 10.247
Authors: Kari R Gillmeyer; Ming-Ming Lee; Alissa P Link; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener Journal: Chest Date: 2018-11-22 Impact factor: 9.410
Authors: S Ashwin Reddy; Sarah L Nethercott; Bharat V Khialani; Andrew A Grace; Claire A Martin Journal: J Interv Card Electrophysiol Date: 2021-04-05 Impact factor: 1.900
Authors: Andrew J Synn; Wenyuan Li; Raúl San José Estépar; Chunyi Zhang; George R Washko; George T O'Connor; Tetsuro Araki; Hiroto Hatabu; Alexander A Bankier; Murray A Mittleman; Mary B Rice Journal: Eur Respir J Date: 2019-09-12 Impact factor: 16.671
Authors: François Potus; Michael W Pauciulo; Elina K Cook; Na Zhu; Alexander Hsieh; Carrie L Welch; Yufeng Shen; Lian Tian; Patricia Lima; Jeffrey Mewburn; Christine L D'Arsigny; Katie A Lutz; Anna W Coleman; Rachel Damico; Brooke Snetsinger; Ashley Y Martin; Paul M Hassoun; William C Nichols; Wendy K Chung; Michael J Rauh; Stephen L Archer Journal: Circulation Date: 2020-03-20 Impact factor: 29.690
Authors: Kari R Gillmeyer; Seppo T Rinne; Mark E Glickman; Kyung Min Lee; Qing Shao; Shirley X Qian; Elizabeth S Klings; Bradley A Maron; Joseph T Hanlon; Donald R Miller; Renda Soylemez Wiener Journal: Circ Cardiovasc Qual Outcomes Date: 2020-05-12
Authors: Jennifer E Ho; Emily K Zern; Emily S Lau; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Robyn Farrell; John A Sbarbaro; Mark W Schoenike; Nicholas E Houstis; Aaron L Baggish; Ravi V Shah; Matthew Nayor; Rajeev Malhotra; Gregory D Lewis Journal: J Am Coll Cardiol Date: 2020-01-07 Impact factor: 24.094